Navigation Links
Alfacell Provides ONCONASE(R) NDA Submission Update
Date:12/5/2008

utical product candidate that works in a manner similar to RNA interference (RNAi) through late-stage clinical trials. The product candidate, ONCONASE, is an RNase that overcomes the challenges of targeting RNA for therapeutic purposes while enabling the development of a new class of targeted therapies for cancer and other life-threatening diseases. For more information, visit www.alfacell.com.

Safe Harbor

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, uncertainty whether the clinical trial results will allow the company to complete submission of a New Drug Application and if a New Drug Application submission is completed, uncertainty whether FDA will file or approve such application, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the company to finance research and development activities, potential challenges to or violations of patents, uncertainties regarding the outcome of clinical trials or differences of opinion in interpreting the results of clinical trials, the company's ability to secure necessary approvals from regulatory agencies, dependence upon third-party vendors, and other risks discussed in the company's periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the company undertakes no obligation to update these statements for revisions or changes after the date of this release.

    Media Contact:                      Investor Contact:
    David Schull or Wendy La
'/>"/>
SOURCE Alfacell Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacells ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines
2. Alfacell Announces ONCONASE(R) Distribution and Marketing Agreement with Megapharm for Israel
3. Alfacell Corporation Announces Preliminary Results From ONCONASE(R) Phase IIIb Clinical Trial
4. Alfacells ONCONASE(R) Shows Potential as Radiation Sensitizer for Lung Cancer Treatment
5. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
6. Alfacell Reports Financial Results for First Quarter of Fiscal 2008
7. Alfacell Corporation to Present at UBS Global Life Sciences Conference
8. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
9. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
10. Sangamo BioSciences Provides Update on Companys 2008 Progress and 2009 Objectives
11. Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... Wis. , March 27, 2015 ... unit shipments of incontinence devices for women. ... but the most gratifying part is the hundreds ... from women whose lives have been positively impacted ... president of InControl. InControl recently released ...
(Date:3/27/2015)... 27, 2015 RnRMarketResearch.com adds ... market research report of 52 pages with latest ... intelligence library. The report "Visceral Pain - Pipeline ... therapeutic development for Visceral Pain, complete with comparative ... target, mechanism of action (MoA), route of administration ...
(Date:3/26/2015)... 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or ... on Omega-3 therapies for cardiovascular disease and overall health, ... common shares of the Corporation (the "Common Shares"). The ... of December 5 th , 2014 to March 4 ... is due on or before April 1, 2015. Interest ...
Breaking Medicine Technology:InControl Medical Surpasses 40,000 Shipments Of Incontinence Devices For Women 2Visceral Pain Pipeline Review H1 2015 Market Research Report 2Visceral Pain Pipeline Review H1 2015 Market Research Report 3Visceral Pain Pipeline Review H1 2015 Market Research Report 4Pivotal Therapeutics announces payment of interest on outstanding convertible notes 2
... - Millennium on track to file sNDA in ... 18 Millennium,Pharmaceuticals, Inc. (Nasdaq: MLNM ) ... large, international Phase III VISTA(1) trial in,patients with ... of,VELCADE, melphalan and prednisone (VMP) demonstrated a highly ...
... 10 minutes - - Landmark Study Reported in ... 18 A landmark publication that,appeared in the Journal ... site blinded clinical study. The paper is entitled "The ... Accuracy of,Melanoma and Equivocal Melanocytic Lesions." The study, ...
Cached Medicine Technology:Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints 2Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints 3Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints 4Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints 5Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints 6Large Blinded Clinical Study Achieves High Accuracy for the Diagnosis of Melanoma Using In Vivo Confocal Microscopy 2Large Blinded Clinical Study Achieves High Accuracy for the Diagnosis of Melanoma Using In Vivo Confocal Microscopy 3
(Date:3/27/2015)... NE (PRWEB) March 27, 2015 Ticket Down ... at the CenturyLink Center in Omaha, Nebraska on Friday, ... possibility that more concert dates will be added in Omaha ... of fan demand. , The Garth Brooks World Tour is ... the latest announcement that Garth Brooks and Trisha Yearwood will ...
(Date:3/27/2015)... Endure Yoga is launching WOD (Workout ... This new program matches yoga poses with functional fitness ... down. This program utilizes yoga to improve recovery, prevent ... , Karen Lefurgy, competitive athlete at CrossFit ... I started Crossfit® training, but quickly, due to time ...
(Date:3/27/2015)... 27, 2015 SMI (Silicon Microstructures, Inc.), ... has launched the SM1120 MEMS based ultra-miniature pressure sensor ... microsensor profile at only 220um x 75um provides ample ... challenging locations. With industry leading in vivo drift ... provides a broad operating pressure range from 0 to ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 Operatic contenders ... of greatness on April 17th. The universally acclaimed baritone ... the 9th annual Opera Idol at The Merion in ... competition, which has drawn aspiring opera singers from around ... showcases some of the finest young talent in the ...
(Date:3/27/2015)... The 2015 Deep Market Research Report ... in-depth study on the current state of the ... on the Chinese situation. , The report provides ... classifications, applications and industry chain structure. The Glutathione ... and Chinese domestic situations including development trends, competitive ...
Breaking Medicine News(10 mins):Health News:Cheap Garth Brooks Tickets for CenturyLink Center in Omaha: Ticket Down Slashes Garth Brooks Concert Tickets in Omaha, NE at the CenturyLink Center 2Health News:Cheap Garth Brooks Tickets for CenturyLink Center in Omaha: Ticket Down Slashes Garth Brooks Concert Tickets in Omaha, NE at the CenturyLink Center 3Health News:Endure Yoga Introduces WOD Recovery Yoga 2Health News:SMI Launches Catheter Mountable Pressure Sensor 2Health News:Opera Idol Competition At The Merion In Evanston 2Health News:Glutathione Industry International and China Market Analysis Report 2015-2020 2Health News:Glutathione Industry International and China Market Analysis Report 2015-2020 3
... in our environment that may cause breast cancer . ... linked to breast cancer has listed 216 compounds, many of ... extensive review of 900 scientific studies concerning humans and rodents ... and water that appear to be a reason behind breast ...
... toll the world over. Almost 100 million girls die every year, ... ,According to a searing report on the prejudices against women, "Because ... developing countries, where a male child remains more valued. ... child development agency - highlights the fact that two million girls ...
... Researchers at University of Southern Maine in Portland have revealed ... far the US government has been denying the possibility. ... Laboratories in New Mexico found that people exposed to DU ... ,DU is a dense, inadequately radioactive metal that is ...
... of North Carolina, Chapel Hill, have found out that middle-aged ... are at a higher risk of retinopathy than others. ... of the eye that can lead to severe vision problems ... the headache history and eye health of 10,902 men and ...
... same level of active therapeutic chemical and produces the ... the harmful toxins, according to UCSF researchers. ... of the active ingredient delta-9-tertrahydrocannibinol, or THC, are reported ... and Therapeutics." ,"We showed in a recent ...
... claimed significant success in the continuing fight to develop ... ,Thomas Pento and Roger HarrisonTwo professors say ... the spread of certain cancerous cells without damaging healthy, ... in fighting lung, prostate and pancreatic cancers without the ...
Cached Medicine News:Health News:List of Compounds That Causes Breast Cancer Identified 2Health News:Female Infanticide and Feticide Continue to Increase 2Health News:History of Migraines Linked to Increased Risk of Retinopathy 2Health News:Smokeless Cannabis Delivery Device Found Efficient and Less Toxic 2Health News:US Professors Develop Fusion Protein to Fight Cancer 2
... A CMV assay for screening donors on ... CMV-PA System uses CMV antigen attached to ... cytomegalovirus. Relative sensitivity and specificity of the ... 99.8% and 99.3% respectively. The use of ...
... microplate agglutination technology. Its is a fully ... testing. PK7200 also handles weak D as ... The Automated Microplate System delivers the very ... that for the past generation has tested ...
... fully automated blood bank ... American market based on ... The ORTHO ProVue™ eliminates ... increasing productivity via random ...
... are in need of MRI exams, many ... scanners. They have heard of, or experienced ... and noisy tubes of supercon scanners - ... people want is a patient-friendly MRI. Now ...
Medicine Products: